Literature DB >> 9834095

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.

T J Yun1, P M Chaudhary, G L Shu, J K Frazer, M K Ewings, S M Schwartz, V Pascual, L E Hood, E A Clark.   

Abstract

We have cloned a TNFR family member from a follicular dendritic cell (FDC)-like cell line, FDC-1. This molecule, FDC-derived receptor-1 (FDCR-1), is identical to osteoprotegerin (OPG), a soluble cytokine that regulates osteoclast differentiation. Recently, OPG/FDCR-1 has been characterized as a second receptor for receptor activator of NF-kappaB ligand (RANKL)/TNF-related activation-induced cytokine (TRANCE), a primarily T-cell restricted TNF family member that augments dendritic cell (DC) function. In this report, we demonstrate that OPG/FDCR-1 is membrane bound on the surface of transfected baby hamster kidney (BHK) and untransfected FDC-1 cells. We also found a restricted OPG/FDCR-1 expression pattern in lymphoid cells, specifically in B cells, DCs and FDC-enriched fractions, which in B cells and DCs is up-regulated by CD40 stimulation. Because OPG/FDCR-1 shares some properties with RANK, the first RANKL/TRANCE receptor, we discuss how the balance between RANK and OPG/FDCR-1 expression could influence immune responses and, ultimately, germinal center formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

3.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

4.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.

Authors:  Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

5.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.

Authors:  Yan Li; Gianluca Toraldo; Aimin Li; Xiaoying Yang; Hongying Zhang; Wei-Ping Qian; M Neale Weitzmann
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 6.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

7.  CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.

Authors:  Susanne Roser-Page; Tatyana Vikulina; Majd Zayzafoon; M Neale Weitzmann
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

8.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

Review 9.  Parathyroid Diseases and T Cells.

Authors:  M Neale Weitzmann; Roberto Pacifici
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

10.  Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.

Authors:  Alessandra Colombini; Giovanni Lombardi; Emanuela Galliera; Giada Dogliotti; Pietro Randelli; Alexander Meerssemann; Giuseppe Mineo; Paolo Cabitza; Massimiliano Marco Corsi
Journal:  Int Orthop       Date:  2010-07-11       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.